Skip to main content

Table 4 Comparison of cost trajectory groups

From: Going beyond the mean: economic benefits of myocardial infarction secondary prevention

Prophylactic medication Traj. Group Full population
N compliant (%)
Multivariable
RRR [95%CI]
p-value Not pre-exposed
N compliant (%)
Multivariable
RRR [95%CI]
p-value
4-class combination
(main analysis)
1 478/1302 (36.7) Ref. 0.0191 192/429 (44.8) Ref. 0.5253
2 71/245 (29.0) 0.89 [0.65; 1.22]   25/62 (40.3) 0.84 [0.47; 1.50]  
3 22/87 (25.3) 0.71 [0.42; 1.21]   8/14 (57.1) 2.29 [0.67; 7.88]  
4 3/31 (9.7) 0.20 [0.06; 0.71]   5/12 (41.7) 0.81 [0.24; 2.77]  
3- & 4-class combinations
(sensitivity analysis)
1 353/1302 (27.1) Ref. 0.5457 134/429 (31.2) Ref. 0.4777
2 65/245 (26.5) 1.07 [0.77; 1.48]   20/62 (32.3) 1.19 [0.65; 2.16]  
3 28/87 (32.2) 1.44 [0.88; 2.34]   2/14 (14.3) 0.38 [0.07; 1.95]  
4 7/31 (22.6) 0.96 [0.40; 2.34]   4/12 (33.3) 1.24 [0.34; 4.46]  
  1. Distribution of compliers and non-compliers across the four trajectory groups (Fig. 4). This analysis investigates whether persons complying with a specific prevention drug combination have a higher probability of being included in the most favorable cost trajectory 1 (used as a reference). A multinomial logistic regression was used to test this hypothesis. The model was estimated for compliance status to a specific drug (main variable of interest shown in the table) and confounder adjustments as described in the methods section (coefficients not shown). P-values < 0.05 are highlighted in bold
  2. Abbreviations: RRR multivariable Relative Risk Ratios, 95% CI 95% Confidence Intervals, Traj Trajectory